Regulatory & Legal

Zymeworks lands $250M from Royalty Pharma in a non-dilutive deal, validating its cancer drug Ziihera and highlighting a new era of biotech financing.

With star-studded advisory board, a new biotech firm aims to turn routine dental visits into a frontline defense against oral cancer.

A Chinese firm's 'Global Pioneer' status in cellular essence sparks debate on the future of biotech in cosmetics, medicine, and global regulation.

Helios Consortium's formal offer for CAB Payments is rejected as 'opportunistic,' igniting a battle for control of the emerging markets payment specialist.

Activist fund GAM escalates its fight in Japan, filing an injunction to stop a Honda-backed squeeze-out it claims values a key auto parts business at zero.

At the India AI Impact Summit, experts warned that AI crises will move at machine speed. Can global diplomacy and safety protocols catch up before it's too late?

Shareholder approval paves the way for cancer therapy innovator VERAXA to go public, aiming to accelerate its next-gen antibody-drug conjugate pipeline.

With its new AI thriller, muVpix is betting on 'engineered storytelling' to finally crack the vertical video code that doomed giants like Quibi.

Canada’s ambitious high-speed rail plan is facing fierce opposition from farmers who say the project threatens their land, livelihood, and food security.

A $4.4 million inventory write-down plunges the world's first private cord blood bank into the red, raising questions about its public banking model.

Healthpeak Properties is launching a new senior housing REIT, Janus Living. What does this strategic pivot mean for investors and the real estate market?

In a radical pivot, diagnostics firm OpGen has become CapForce, an AI-powered investment bank targeting a $10B niche. Can it trade microbes for money?

SmartCentres REIT pushes back a key deadline with its CEO's private firm, spotlighting a complex web of strategy, governance, and founder influence.

FMC Corporation declared a steady dividend, but the routine payout masks deep financial struggles, a recent credit downgrade, and a strategy to shed assets.

AMTD Digital reports explosive growth, but a closer look reveals a complex strategy involving media, SPACs, and a recent change in auditors.

The last-mile delivery firm reports a 9.1% revenue bump, but its net loss quintuples to $2.2M amid heavy spending and a risky diversification plan.

Facing delisting for being a 'public shell,' XTL Biopharma plans an appeal while its new acquisition and valuable IP hang in the balance.

TRG Latin America Acquisitions Corp. raises $200M in an IPO, targeting Argentina with the backing of emerging market veterans from The Rohatyn Group.

The biotech firm's stock surged after announcing a massive share repurchase, a bold move balancing shareholder value with its high-stakes R&D pipeline.

Estonian food group PRFoods reports staggering losses as home market revenue plummets over 70%, forcing a strategic pivot to its stable UK subsidiary.